139 related articles for article (PubMed ID: 24140600)
1. Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity.
Bhakta V; Gierczak RF; Sheffield WP
J Biotechnol; 2013 Dec; 168(4):373-81. PubMed ID: 24140600
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity.
Gierczak RF; Bhakta V; Xie M; Sheffield WP
J Biotechnol; 2015 Aug; 208():54-62. PubMed ID: 26043905
[TBL] [Abstract][Full Text] [Related]
3. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.
Roddick LA; Bhakta V; Sheffield WP
BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622
[TBL] [Abstract][Full Text] [Related]
4. Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.
Scott BM; Matochko WL; Gierczak RF; Bhakta V; Derda R; Sheffield WP
PLoS One; 2014; 9(1):e84491. PubMed ID: 24427287
[TBL] [Abstract][Full Text] [Related]
5. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
6. Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor.
Gierczak RF; Pepler L; Bhagirath V; Liaw PC; Sheffield WP
Thromb Res; 2014 Nov; 134(5):1142-9. PubMed ID: 25242242
[TBL] [Abstract][Full Text] [Related]
7. The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa.
Sheffield WP; Bhakta V
Biochem Biophys Res Commun; 2016 Feb; 470(3):710-713. PubMed ID: 26797521
[TBL] [Abstract][Full Text] [Related]
8. Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells.
Gierczak RF; Sutherland JS; Bhakta V; Toltl LJ; Liaw PC; Sheffield WP
J Thromb Haemost; 2011 Dec; 9(12):2424-35. PubMed ID: 21972922
[TBL] [Abstract][Full Text] [Related]
9. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
[TBL] [Abstract][Full Text] [Related]
10. Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins.
Sheffield WP; Eltringham-Smith LJ; Bhakta V; Gataiance S
Thromb Haemost; 2012 May; 107(5):972-84. PubMed ID: 22370677
[TBL] [Abstract][Full Text] [Related]
11. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition.
Sutherland JS; Bhakta V; Filion ML; Sheffield WP
Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704
[TBL] [Abstract][Full Text] [Related]
12. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786
[TBL] [Abstract][Full Text] [Related]
13. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
[TBL] [Abstract][Full Text] [Related]
14. The P6-P2 region of serpins is critical for proteinase inhibition and complex stability.
Chaillan-Huntington CE; Gettins PG; Huntington JA; Patston PA
Biochemistry; 1997 Aug; 36(31):9562-70. PubMed ID: 9236002
[TBL] [Abstract][Full Text] [Related]
15. Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis.
Bhakta V; Hamada M; Nouanesengsy A; Lapierre J; Perruzza DL; Sheffield WP
Sci Rep; 2021 Mar; 11(1):5565. PubMed ID: 33692375
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin.
Mast AE; Enghild JJ; Pizzo SV; Salvesen G
Biochemistry; 1991 Feb; 30(6):1723-30. PubMed ID: 1704258
[TBL] [Abstract][Full Text] [Related]
17. Expression and purification of recombinant human alpha1-proteinase inhibitor and its single amino acid substituted variants in Escherichia coli for enhanced stability and biological activity.
Agarwal S; Jha S; Sanyal I; Amla DV
J Biotechnol; 2010 May; 147(1):64-72. PubMed ID: 20346993
[TBL] [Abstract][Full Text] [Related]
18. Protein engineering of chimeric Serpins: an investigation into effects of the serpin scaffold and reactive centre loop length.
Bottomley SP; Stone SR
Protein Eng; 1998 Dec; 11(12):1243-7. PubMed ID: 9930674
[TBL] [Abstract][Full Text] [Related]
19. Role of the P2 residue in determining the specificity of serpins.
Djie MZ; Le Bonniec BF; Hopkins PC; Hipler K; Stone SR
Biochemistry; 1996 Sep; 35(35):11461-9. PubMed ID: 8784202
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for serpin inhibitor activity.
Wright HT; Scarsdale JN
Proteins; 1995 Jul; 22(3):210-25. PubMed ID: 7479695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
